Hard template–salt template double template preparation of heteroatom-doped hierarchical porous carbon and its electrochemical properties
RSC Advances · 2025 · 15 (4) · 2582-2590
DOI: 10.1039/d4ra08818b ↗Kurz gefasst
Fachartikel in der Zeitschrift RSC Advances, 2025. Verfasst von Fangfang Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Materials Science and Physics, China University of Mining and Technology Xuzhou 221116 China liuff4069@163.com njn0516@cumt.edu.cn. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Heteroatom-doped hierarchical porous carbon (AF-MMTC) was prepared with hard template and salt template dual templating agents, and the salt template and the hard template synergistically construct pore structures at different scales.
Autor:innen und Institutionen
- School of Materials Science and Physics, China University of Mining and Technology Xuzhou 221116 China liuff4069@163.com njn0516@cumt.edu.cn.
ORCID-Profile: Fangfang Liu, Jinan Niu
Förderung
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Liu, F., Zhang, F., & Niu, J. (2025). Hard template–salt template double template preparation of heteroatom-doped hierarchical porous carbon and its electrochemical properties. RSC Advances, 15(4), 2582-2590. https://doi.org/10.1039/d4ra08818b
Vancouver
Liu F, Zhang F, Niu J. Hard template–salt template double template preparation of heteroatom-doped hierarchical porous carbon and its electrochemical properties. RSC Advances. 2025;15(4):2582-2590. doi:10.1039/d4ra08818b
BibTeX
@article{Liu2025,
author = {Liu, Fangfang and Zhang, Fenglei and Niu, Jinan},
title = {Hard template–salt template double template preparation of heteroatom-doped hierarchical porous carbon and its electrochemical properties},
journal = {RSC Advances},
year = {2025},
volume = {15},
number = {4},
pages = {2582--2590},
doi = {10.1039/d4ra08818b}
}
EUVIMED